Eftilagimod Alpha Plus Pembrolizumab in First-Line Metastatic Non–Small Cell Lung Cancer: Results From a PD-L1–Unselected Population in the TACTI-002 Study Patients with stage IB to IIB MF received ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results